PH12013501924A1 - Anticoagulant antidotes - Google Patents
Anticoagulant antidotesInfo
- Publication number
- PH12013501924A1 PH12013501924A1 PH1/2013/501924A PH12013501924A PH12013501924A1 PH 12013501924 A1 PH12013501924 A1 PH 12013501924A1 PH 12013501924 A PH12013501924 A PH 12013501924A PH 12013501924 A1 PH12013501924 A1 PH 12013501924A1
- Authority
- PH
- Philippines
- Prior art keywords
- antidotes
- anticoagulant
- anticoagulant antidotes
- anticoagulants
- relates
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title abstract 3
- 229940127219 anticoagulant drug Drugs 0.000 title abstract 3
- 239000000729 antidote Substances 0.000 title abstract 2
- 229940075522 antidotes Drugs 0.000 title abstract 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003850 dabigatran Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469207P | 2011-03-30 | 2011-03-30 | |
| PCT/EP2012/055397 WO2012130834A1 (en) | 2011-03-30 | 2012-03-27 | Anticoagulant antidotes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013501924A1 true PH12013501924A1 (en) | 2017-10-25 |
Family
ID=45876804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/501924A PH12013501924A1 (en) | 2011-03-30 | 2012-03-27 | Anticoagulant antidotes |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8821871B2 (enExample) |
| EP (1) | EP2691156A1 (enExample) |
| JP (1) | JP2014515740A (enExample) |
| KR (1) | KR20140009437A (enExample) |
| CN (1) | CN103476459A (enExample) |
| AP (1) | AP2013007046A0 (enExample) |
| AR (1) | AR085758A1 (enExample) |
| BR (1) | BR112013025031A2 (enExample) |
| CA (1) | CA2827787A1 (enExample) |
| CL (1) | CL2013002551A1 (enExample) |
| CO (1) | CO6771448A2 (enExample) |
| EA (1) | EA201301090A1 (enExample) |
| EC (1) | ECSP13012997A (enExample) |
| IL (1) | IL227653A0 (enExample) |
| MA (1) | MA34978B1 (enExample) |
| MX (1) | MX2013011092A (enExample) |
| PE (1) | PE20140964A1 (enExample) |
| PH (1) | PH12013501924A1 (enExample) |
| SG (1) | SG193552A1 (enExample) |
| TN (1) | TN2013000388A1 (enExample) |
| TW (1) | TW201302796A (enExample) |
| UY (1) | UY33994A (enExample) |
| WO (1) | WO2012130834A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| MX349514B (es) | 2011-11-29 | 2017-08-02 | Perosphere Inc | Agentes de reversion anticoagulante. |
| NZ714765A (en) | 2013-06-06 | 2021-12-24 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
| CA2913691C (en) * | 2013-07-30 | 2022-01-25 | Janssen Sciences Ireland Uc | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| KR101523503B1 (ko) * | 2013-09-17 | 2015-05-29 | 강원대학교산학협력단 | 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물 |
| JP2016539926A (ja) | 2013-10-25 | 2016-12-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗凝血薬の解毒剤 |
| EP2980218A1 (en) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
| EP3784281A4 (en) * | 2018-04-27 | 2022-02-16 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | IN VIVO GENE THERAPY USING ADMINISTRATION OF A LENTIVIRAL GENE CONSTRUCT |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0654085T3 (da) | 1992-01-23 | 1997-09-22 | Merck Patent Gmbh | Monomere og dimere antistof-fragment-fusionsproteiner |
| DE4203965A1 (de) | 1992-02-11 | 1993-08-12 | Max Planck Gesellschaft | Antidot fuer hirudin und synthetische thrombininhibitoren |
| ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1994029347A1 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Antibody fragments in therapy |
| AT404357B (de) | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
| DE19605126A1 (de) | 1996-02-12 | 1997-08-14 | Basf Ag | Thrombinmuteine als Antidot für Thrombininhibitoren |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| AU2001261024A1 (en) | 2000-04-12 | 2001-10-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| CN1911965B (zh) | 2001-01-17 | 2013-05-29 | 新兴产品开发西雅图有限公司 | 结合域-免疫球蛋白融合蛋白 |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
| PL3078743T3 (pl) | 2007-09-28 | 2020-11-02 | Portola Pharmaceuticals, Inc. | Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania |
| WO2011023653A1 (en) | 2009-08-24 | 2011-03-03 | Boehringer Ingelheim International Gmbh | Emergency interventions of active charcoal with dabigatran etexilate overdosing |
| AR079944A1 (es) * | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2012
- 2012-03-27 EA EA201301090A patent/EA201301090A1/ru unknown
- 2012-03-27 KR KR1020137025877A patent/KR20140009437A/ko not_active Withdrawn
- 2012-03-27 MA MA36273A patent/MA34978B1/fr unknown
- 2012-03-27 EP EP12710300.0A patent/EP2691156A1/en not_active Withdrawn
- 2012-03-27 SG SG2013070719A patent/SG193552A1/en unknown
- 2012-03-27 JP JP2014501575A patent/JP2014515740A/ja not_active Ceased
- 2012-03-27 MX MX2013011092A patent/MX2013011092A/es not_active Application Discontinuation
- 2012-03-27 WO PCT/EP2012/055397 patent/WO2012130834A1/en not_active Ceased
- 2012-03-27 CA CA2827787A patent/CA2827787A1/en not_active Abandoned
- 2012-03-27 PE PE2013002078A patent/PE20140964A1/es not_active Application Discontinuation
- 2012-03-27 AP AP2013007046A patent/AP2013007046A0/xx unknown
- 2012-03-27 BR BR112013025031A patent/BR112013025031A2/pt not_active IP Right Cessation
- 2012-03-27 PH PH1/2013/501924A patent/PH12013501924A1/en unknown
- 2012-03-27 CN CN2012800157134A patent/CN103476459A/zh active Pending
- 2012-03-28 US US13/432,296 patent/US8821871B2/en active Active
- 2012-03-29 UY UY0001033994A patent/UY33994A/es unknown
- 2012-03-29 AR ARP120101085A patent/AR085758A1/es unknown
- 2012-03-29 TW TW101111195A patent/TW201302796A/zh unknown
-
2013
- 2013-07-25 IL IL227653A patent/IL227653A0/en unknown
- 2013-09-05 CL CL2013002551A patent/CL2013002551A1/es unknown
- 2013-09-20 CO CO13224736A patent/CO6771448A2/es unknown
- 2013-09-26 TN TNP2013000388A patent/TN2013000388A1/fr unknown
- 2013-10-25 EC ECSP13012997 patent/ECSP13012997A/es unknown
-
2014
- 2014-07-22 US US14/337,357 patent/US20140377265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR085758A1 (es) | 2013-10-23 |
| US20120276123A1 (en) | 2012-11-01 |
| TN2013000388A1 (en) | 2015-01-20 |
| CL2013002551A1 (es) | 2014-02-14 |
| SG193552A1 (en) | 2013-11-29 |
| MA34978B1 (fr) | 2014-03-01 |
| EA201301090A1 (ru) | 2014-05-30 |
| KR20140009437A (ko) | 2014-01-22 |
| JP2014515740A (ja) | 2014-07-03 |
| MX2013011092A (es) | 2013-12-06 |
| ECSP13012997A (es) | 2013-12-31 |
| US8821871B2 (en) | 2014-09-02 |
| CO6771448A2 (es) | 2013-10-15 |
| US20140377265A1 (en) | 2014-12-25 |
| NZ613543A (en) | 2015-07-31 |
| WO2012130834A1 (en) | 2012-10-04 |
| IL227653A0 (en) | 2013-09-30 |
| AP2013007046A0 (en) | 2013-08-31 |
| CN103476459A (zh) | 2013-12-25 |
| PE20140964A1 (es) | 2014-08-17 |
| CA2827787A1 (en) | 2012-10-04 |
| EP2691156A1 (en) | 2014-02-05 |
| TW201302796A (zh) | 2013-01-16 |
| UY33994A (es) | 2012-09-28 |
| BR112013025031A2 (pt) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000366A1 (en) | Anticoagulant antidotes | |
| MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
| TN2013000388A1 (en) | Anticoagulant antidotes | |
| EP2706991A4 (en) | IMMUNOGENIC COMPOSITION WITH SEVERAL ANTIGENES, AND METHODS THEREFOR, AND USES THEREOF | |
| PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
| CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| BR112014030278A2 (pt) | anticorpo, e, composição. | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| WO2013021279A3 (en) | Highly galactosylated antibodies | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| WO2012109238A3 (en) | Methods for increasing immune responses using agents that directly bind to and activate ire-1 | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| WO2014097318A3 (en) | Agents for eliminating tumour-initiating cells | |
| EA201491455A1 (ru) | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| UY35795A (es) | Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran | |
| HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства | |
| TH1301006508B (th) | องค์ประกอบที่รวมถึงโพลีเตตระฟลูออโรเอธิลีน และกระบวนการสำหรับการเตรียมองค์ประกอบของสิ่งนั้น | |
| CL2012001927A1 (es) | Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo. |